A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients with Pediatric-Onset Hypophosphatasia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 04 Jul 2017 This study has been completed in Germany as per European Clinical Trials Database.(Global end date- 2017-04-12)
- 17 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 17 Feb 2017 Status changed from recruiting to active, no longer recruiting.